Industry top-down
Medical Devices
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The medical device industry demonstrated robust overall revenue growth, recording a median revenue growth rate of 10.29%. Numerous companies, including Boston Scientific, Penumbra, and Dexcom, achieved double-digit revenue growth. However, company-specific profitability metrics showed mixed trends. While companies like Penumbra, GE Healthcare, and Boston Scientific recorded high EPS growth, some companies experienced a decrease in EPS or negative growth despite revenue growth. This suggests that despite the overall revenue expansion across the industry, performance varied depending on each company's efforts in profitability improvement and cost control.
- Industrial intermediate sales grew by 10.29%, with many companies recording double-digit growth
- Despite sales growth, EPS showed significant variation by company
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| ABTABBOTT LABORATORIES | FY2026 Q1 | $10.36B | +4.0% | $0.76 | +8.6% | — |
| SYKSTRYKER CORP | FY2026 Q1 | $5.87B | +11.9% | $1.69 | -17.6% | — |
| MDTMedtronic plc | FY2026 Q3 | $24.61B | +3.5% | $2.79 | +22.9% | — |
| BSXBOSTON SCIENTIFIC CORP | FY2026 Q1 | $4.66B | +20.9% | $0.45 | +36.4% | — |
| EWEdwards Lifesciences Corp | FY2026 Q1 | $1.41B | +6.2% | $0.61 | +5.2% | — |
| DXCMDEXCOM INC | FY2026 Q1 | $1.04B | +12.5% | $0.27 | -25.0% | — |
| GEHCGE HealthCare Technologies Inc. | FY2026 Q1 | $4.78B | +2.7% | $1.23 | +51.9% | — |
| PENPenumbra Inc | FY2026 Q1 | $324.14M | +16.3% | $1.00 | +257.1% | — |
| GMEDGLOBUS MEDICAL INC | FY2026 Q1 | $598.12M | -1.4% | $0.54 | — | — |
| PODDINSULET CORP | FY2026 Q1 | $569M | +28.8% | $0.50 | -31.5% | — |
| MASIMASIMO CORP | FY2026 Q1 | $372M | +9.5% | $-3.12 | — | — |
| BRKRBRUKER CORP | FY2026 Q1 | $801.4M | +11.0% | $0.11 | -68.6% | — |
| BIOBIO-RAD LABORATORIES, INC. | FY2026 Q1 | $585.4M | -4.2% | $2.29 | -83.0% | — |
| BIO-BBIO-RAD LABORATORIES, INC. | FY2026 Q1 | $585.4M | -4.2% | $2.29 | -83.0% | — |
| GKOSGLAUKOS Corp | FY2026 Q1 | $106.66M | +24.6% | $-0.32 | — | — |
| LIVNLivaNova PLC | FY2026 Q1 | $316.86M | +7.4% | $-6.01 | — | — |
| IRTCiRhythm Holdings, Inc. | FY2026 Q1 | $158.68M | +20.3% | $-0.97 | — | — |
| HAEHAEMONETICS CORP | FY2026 Q3 | $1.03B | +6.7% | $2.14 | +13.2% | — |
| ITGRInteger Holdings Corp | FY2026 Q1 | $437.39M | +7.3% | $-0.66 | — | — |
| AXGNAxogen, Inc. | FY2026 Q1 | $48.56M | +17.4% | $-0.08 | — | — |
| ESTAESTABLISHMENT LABS HOLDINGS INC. | FY2026 Q1 | $41.38M | +11.3% | $-0.70 | — | — |
| NVCRNovoCure Ltd | FY2026 Q1 | $154.99M | +11.9% | $-0.31 | — | — |
| NEOGNEOGEN CORP | FY2026 Q3 | $669.2M | -2.7% | $-2.21 | — | — |
| PRCTPROCEPT BioRobotics Corp | FY2026 Q1 | $69.16M | +55.3% | $-0.45 | — | — |
| ALMRAlamar Biosciences, Inc. | FY2026 Q1 | $13.09M | — | $-0.68 | — | — |
| AHCOAdaptHealth Corp. | FY2026 Q1 | $777.88M | -1.8% | $-0.05 | — | — |
| ENOVEnovis CORP | FY2026 Q1 | $558.83M | +8.2% | $-0.98 | — | — |
| IARTINTEGRA LIFESCIENCES HOLDINGS CORP | FY2026 Q1 | $382.65M | +3.7% | $-0.33 | — | — |
| INSPInspire Medical Systems, Inc. | FY2026 Q1 | $201.32M | +22.7% | $0.10 | — | — |
| BFLYButterfly Network, Inc. | FY2026 Q1 | $21.23M | +20.2% | $-0.06 | — | — |
| AVNSAVANOS MEDICAL, INC. | FY2026 Q1 | $167.5M | +0.8% | $0.14 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).